Sairopa has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis (EXEL) involving ADU-1805, an anti-SIRPalpha antibody with the potential to enhance the immune system’s ability to combat cancer. Under the terms of the agreement, Exelixis has an exclusive option to license worldwide development and commercialization rights for ADU-1805 and other anti-SIRPalpha antibodies following the review of data from Sairopa’s phase 1 clinical studies. As part of its collaboration with Exelixis, Sairopa has previously received from Exelixis an upfront payment of $40M, a $35M milestone payment upon Investigational New Drug clearance of ADU-1805 with the FDA, and $35M in milestone payments linked to advances within the clinical development of ADU-1805, in monotherapy as well as in combination with a PD-1 inhibitor. The safety and pharmacokinetics of ADU-1805 are currently being evaluated in a first-in-human phase 1 study.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXEL:
- Exelixis downgraded to Neutral at BofA following 37% rally
- Exelixis downgraded to Neutral from Buy at BofA
- FDA tells Exelixis supplemental NDA for cabozantinib to be discussed in March
- Exelixis director Poste sells 30,000 common shares
- Exelixis general counsel Hessekiel sells 50,000 common shares
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
